MedTrace Logo

A First-in-Human Study of BNZ132-1-40

NCT03046459 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-06-22

No results posted yet for this study

Summary

This is an open-label, single ascending dose study to characterize the safety and PK/PD profile of IV BNZ132-1-40, a novel peptide inhibitor of multiple cytokines in the IL-2 family.

Conditions

  • Healthy

Interventions

BIOLOGICAL

BNZ132-1-40

pegylated peptide inhibiting IL-2, IL-9 and IL-15

Sponsors & Collaborators

  • Celerion

    collaborator INDUSTRY

  • Bioniz Therapeutics

    lead INDUSTRY

Principal Investigators

  • Paul A Frohna, MD, PhD · Bioniz Therapeutics, Inc.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-06-05
Completion
2017-06-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03046459 on ClinicalTrials.gov